에피제네틱스 시장 보고서 : 제품·기술·용도·지역별(2024-2032년)

The global epigenetics market size reached US$ 2.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.2 Billion by 2032, exhibiting a growth rate (CAGR) of 12.6% during 2024-2032.

Epigenetics refers to the study of heritable changes in the expression of active and inactive genes. The sources of changes can be both external from environmental factors or internal factors, such as age and disease. It is commonly used for the diagnosis of underlying conditions and preventing them from getting transferred to the future generations. It involves the use of various enzymes, instruments, such as sequencers, spectrometers and sonicators, reagents and kits. They are commonly utilized for deoxyribonucleic acid (DNA) and histone methylation, non-coding ribonucleic acid (RNA), acetylation and phosphorylation. As a result, epigenetics is widely used for the diagnosis, monitoring and treatment of oncological, autoimmune, metabolic, cardiovascular and pain disorders.

Epigenetics Market Trends:

The increasing prevalence of cancer and autoimmune deficiency syndrome (AIDS) across the globe is among the key factors driving the market growth. Moreover, the widespread adoption of epigenetic solutions for non-oncological ailments is providing a thrust to the market growth. The sudden outbreak of the coronavirus disease (COVID-19) is also providing growth opportunities to market players. For instance, various research institutes are running advanced epigenetic tests to study the impact of the virus on the human genome and are developing tools for early recognition, risk evaluations and developing personalized treatments. Additionally, the development of DNA and RNA modifying enzymes, such as acetylases, methyltransferases, reverse transcriptase and ligases, and the launch of highly sensitive and selective tests and instruments, are acting as other growth-inducing factors. These innovations facilitate the assessment of locus-specific DNA methylation on a genome. Other factors, including extensive research and development (R&D) activities in the field of biotechnology, along with significant improvements in the healthcare infrastructure, especially in the developing economies, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global epigenetics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on product, technology, and application.

Breakup by Product:

Reagents

Kits

Chip Sequencing Kit

Whole Genomic Amplification Kit

Bisulfite Conversion Kit

RNA Sequencing Kit

Others

Instruments

Enzymes

Services

Breakup by Technology:

DNA Methylation

Histone Methylation

Histone Acetylation

Large Non-Coding RNA

MicroRNA Modification

Chromatin Structures

Breakup by Application:

Oncology

Solid Tumors

Liquid Tumors

Non-Oncology

Inflammatory Diseases

Metabolic Diseases

Infectious Diseases

Cardiovascular Diseases

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abcam plc, Active Motif Inc., Agilent Technologies Inc., Diagenode Diagnostics (Hologic Inc), Illumina Inc., Merck KGaA, PerkinElmer Inc., Roche Holding AG, Thermo Fisher Scientific Inc. and Zymo Research Corporation.

Key Questions Answered in This Report

• 1. How big is the global epigenetics market?
• 2. What is the expected growth rate of the global epigenetics market during 2024-2032?
• 3. What are the key factors driving the global epigenetics market?
• 4. What has been the impact of COVID-19 on the global epigenetics market?
• 5. What is the breakup of the global epigenetics market based on the product?
• 6. What is the breakup of the global epigenetics market based on the technology?
• 7. What is the breakup of the global epigenetics market based on the application?
• 8. What are the key regions in the global epigenetics market?
• 9. Who are the key players/companies in the global epigenetics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Epigenetics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Reagents
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Kits
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Chip Sequencing Kit
    • 6.2.2.2 Whole Genomic Amplification Kit
    • 6.2.2.3 Bisulfite Conversion Kit
    • 6.2.2.4 RNA Sequencing Kit
    • 6.2.2.5 Others
  • 6.2.3 Market Forecast
• 6.3 Instruments
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Enzymes
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Services
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Technology

• 7.1 DNA Methylation
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Histone Methylation
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Histone Acetylation
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Large Non-Coding RNA
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 MicroRNA Modification
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 Chromatin Structures
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by Application

• 8.1 Oncology
  • 8.1.1 Market Trends
  • 8.1.2 Key Segments
    • 8.1.2.1 Solid Tumors
    • 8.1.2.2 Liquid Tumors
  • 8.1.3 Market Forecast
• 8.2 Non-Oncology
  • 8.2.1 Market Trends
  • 8.2.2 Key Segments
    • 8.2.2.1 Inflammatory Diseases
    • 8.2.2.2 Metabolic Diseases
    • 8.2.2.3 Infectious Diseases
    • 8.2.2.4 Cardiovascular Diseases
    • 8.2.2.5 Others
  • 8.2.3 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Abcam plc
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
    • 14.3.1.4 SWOT Analysis
  • 14.3.2 Active Motif Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Agilent Technologies Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
    • 14.3.3.3 Financials
    • 14.3.3.4 SWOT Analysis
  • 14.3.4 Diagenode Diagnostics (Hologic Inc)
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Illumina Inc.
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 Merck KGaA
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 PerkinElmer Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Roche Holding AG
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
    • 14.3.8.3 Financials
  • 14.3.9 Thermo Fisher Scientific Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
    • 14.3.9.3 Financials
    • 14.3.9.4 SWOT Analysis
  • 14.3.10 Zymo Research Corporation
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio